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As the ribosomal synthesis of a nascent polypeptide progresses, the chain immediately 
undergoes folding into a-helical and b-strand secondary structure elements. While the 
protein matures, the polypeptide collapses into higher order constructs that ultimately 
form the native protein state. Since this state represents only a local minimum on the 
energy landscape of protein folding, the living cell has to continuously ensure an intact 
proteome through elaborate cellular mechanisms. However, some proteins have a high 
intrinsic propensity to escape these mechanisms and re-fold, which initiates protein 
aggregation into b-sheet rich protein nanofibrils (PNF).  
The accumulation of PNF in living cells can be problematic and trigger a number of 
diseases. Nevertheless, some organisms utilize the robustness of these aggregates to build 
protective shells or to form biofilms. The insight that PNF fulfil physiological functions 
in nature, has led to the discovery of many, biotechnological useful, material properties. 
PNF based materials are environmentally friendly and can be specifically designed 
through genetic engineering. A diameter of less than 10 nm confers an enormous surface 
area over volume ratio to the nanofibrils. In addition, the fibrils have mechanical 
properties that are similar to spider dragline silk, natures ‘high performance polymer’.  
To exploit these properties biotechnologically, I aimed to solve critical challenges that 
delay real-world applications. First, I developed a strategy that allowed me to fibrillate 
the proteins Sup35 and Ure2 from Saccharomyces cerevisiae in a manner that ensures a 
maximal functionality of the active domains displayed on the surface of the nanofibrils. 
Second, I designed a set of biotechnological relevant fibrils to show that our fibrillation 
concept is universally applicable. Therefore, I assembled fibrils with an exceptional 
antibody binding capacity, antibiotic degrading properties, and compiled a reaction 
cascade of immobilized enzymes that process xylan biomass. Third, I characterized these 
functionalized fibrils in detail, which goes beyond the proof-of-concept stage. Fourth, I 
have raised an important question that concerns the choice of the proper methodology to 
upscale the production of PNF, to produce economical competitive products. As a first 
step towards this end goal, I used the methylotrophic yeast Komagataella pastoris as a 
host to produce ready-to-use fibrils, which can be separated from the yeast cells using 
centrifugation and water. 
Still, additional major efforts are necessary to develop industrial-scale production 
methods. Another issue that awaits a solution, is the transfer of the nanofibril mechanical 
properties to macro-scale structures. To finally be able to close the gap between the 
laboratory to marketable product, a collaboration with industrial partners is required. 
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The advent of fully synthetic materials in the beginning of the 20th century 
(American Chemical Society, 2018), has triggered the development of material 
science. The versatility and low cost of plastics have led to an enormous variety 
of applications in industry, aerospace, as packaging materials, in electronic 
devices, medical applications, and other consumables (Gilbert, 2017), which our 
modern society is completely dependent upon. Since 1950 more than 8,300 
million metric tons of plastics were produced (Geyer et al., 2017). However, this 
success also comes at a high environmental cost. An absurd high fraction of these 
artificial and robust materials accumulates in landfills or in the marine biosphere, 
where they pollute all kind of lifeforms and sensitive ecosystems. Plastic debris 
is found even in the most remote locations on Earth such as Antarctica (Waller 
et al., 2017). At the same time, the high concentration of microplastic in the 
ocean also poses a health hazard to humankind (Wright and Kelly, 2017). 
Among other factors, the environmental perspective and the serious threat for 
world-health initiated a new race for natural alternatives and has led to the 
discovery of new scaffolds that could replace the all dominant synthetic plastics 
(Sun, 2005, Satam et al., 2018). 
 In addition to substitutes to plastic, there is a growing trend to replace other 
common materials that are essentials of modern life, with materials from natural 
and renewable sources that could minimize the environmental damage 
(Varghese and Mittal, 2018). This transition to a circular and biobased economy 
influences the development of medical applications, construction of buildings, 
and the fabrics used for clothing, with the result that the demand for new 
environmentally friendly solutions in every facet of material science is 
enormous. Another driving force that naturally accelerates the field of material 
science is the technological development. New technologies require novel 
materials with specifically tailored nanostructures (Yaghi et al., 2003). 
The main focus this thesis will be on the biotechnological aspect of material 
science. Very popular for modern biotechnological processes, are materials that 
1 Introduction 
14 
 
are biocompatible, degradable and that can be precisely engineered on a 
nanoscale. A scaffold that fulfils these requirements are materials that are based 
on the ordered self-assembly of proteins into nanofibrils. The beauty of protein 
nanomaterials is that they can be dynamically engineered by introducing 
modifications in the genetic code, which sets no limits on the creativity. For 
instance, genetic manipulations can be used to equip protein nanomaterials with 
hitherto foreign functionalities. Furthermore, proteins are heterologously 
expressed by microorganisms and do not demand the use of environmentally 
threating chemicals in any part of their production.  
The realization to harness this kind of natural occurring material for purposes 
other than those intended by nature occurred 18 years ago (MacPhee and 
Dobson, 2000). In the past 18 years, the field has slowly but steadily gained 
momentum and has led to a wide range of proof-of-concept materials, but to the 
best of my knowledge there is no industrial scale or medical implementation yet 
(Wang et al., 2018). 
Superficially, the aim of this thesis is to deliver an important contribution in 
the quest of developing protein nanomaterials that may one day be used for 
biotechnological applications. Hence, I identified some key obstacles that need 
to be conquered before this technology is mature for practical use.  
First, I targeted to improve the protocols for assembling the protein 
nanofibrils (PNF), in order to ensure that the functionality of the active domains 
displayed on the fibrils is completely retained. Second, I aimed to develop a 
generic expression platform that is appropriate for upscaling the production of 
protein nanomaterials. Third, I intended to study materials with high 
biotechnological relevance beyond the proof-of-concept stage.    
Even though protein materials may never replace synthetic plastics 
themselves, they occupy a niche within biotechnology and biomedicine that 
cannot be filled with synthetic alternatives. The potential of biobased materials 
in general, but in particular, protein nanomaterials shall be outlined in this work.  
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2.1 Biobased Materials 
Biobased materials are as the name suggests materials that are derived from a 
biological source, so called biotic materials as for instance wood, cotton, spider 
silk, etc. Biotic materials become biobased materials once they have been 
engineered or processed, but the term implies nothing with respect to its intended 
use (Masutani and Kimura, 2015).  
In popular media the word ‘biomaterial’ is often used as a synonym for 
materials from a biological origin, but this is not appropriate in this case. An 
accurate definition of ‘biomaterial’ is ‘a substance that has been engineered to 
take a form which, alone or as part of a complex system, is used to direct, by 
control of interactions with components of living systems, the course of any 
therapeutic or diagnostic procedure’ (Williams, 2014). Improvement of 
worldwide healthcare solutions is an ever-pending area that demands innovative 
biomaterials. In this field, the value of natural polymers for medical applications 
increases steadily, since they originate from renewable sources and because they 
are biocompatible as well as biodegradable (Balaji et al., 2018). Applications of 
carbohydrate-based materials such as chitosan or cellulose include, among 
others, targeted drug delivery, tissue engineering, and wound healing (Balaji et 
al., 2018, Mohite and Patil, 2014). 
In addition to medical applications, recent research shows that carbohydrates 
are an interesting scaffold in other areas as well. For instance, nanocellulose 
fibrils were assembled into macroscale fibers that are far superior over other 
natural polymers in terms of mechanical durability (Mittal et al., 2018). 
Furthermore, the combination of carbohydrate fibrils with inorganic 
nanoparticles, creates several interesting prospects for biotechnology, which 
have been reviewed in depth by Jebali and co-workers (Jebali et al., 2017).  
2 Background 
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Biobased materials can also be constructed using programable DNA. 
Sophisticated DNA sequences can self-assemble by an bottom-up approach at 
nanometer special resolution to simple junction tiles and to complex 3D 
structures (Nick McElhinny and Becker, 2014). The same mechanisms can be 
exploited to assemble DNA based hydrogels and advanced molecular machines. 
(Li et al., 2018). 
2.2 Protein Materials 
The ensemble of biobased nanomaterials is not complete, without a discussion 
of protein-based materials. Proteins are not only, for example, biological signal 
transducers and nano-sized catalysts, but in addition form the material basis for 
life. Protein structures, compared to inorganic structures, combine the seemingly 
incompatible properties strength, robustness and adaptability (Buehler and 
Yung, 2010). The material properties are encoded within the protein sequence 
and controlled in most cases by post-translational modifications, auxiliary 
proteins, and the surrounding chemical conditions. Therefore, protein-based 
materials are able to cover a broad spectrum of material properties and can be 
extremely rigid or elastic, dependent on the intended application. 
Actin and tubulin filaments are dynamic assemblies and components of the 
cytoskeleton. The polymerization of the globular proteins is reversible and is 
dependent upon ATP or GTP hydrolysis. These fibrils are not the strongest 
biological polymers, since preserving the dynamics, goes along with weaker 
intramolecular interactions, that consequently leads to a less rigid material 
(Knowles and Buehler, 2011).  
Collagen and elastin are the main components of the extracellular matrix and 
connective tissues. Bundles of elastin are crosslinked by oxidative deamination 
of lysines from tropoelastin and confer elasticity to vertebrate tissues. To 
assemble collagen, the precursor peptide undergoes several post-translational 
modifications inside the cell before three polypeptide chains form a triple helix 
known as procollagen. Outside the cell, procollagen is glycosylated and 
covalently linked to other triple helix strands in order to form the mature fiber.   
To orchestrate the assembly of keratin fibrils does not require auxiliary 
proteins and co-factors. Initially, monomers of type I and type II keratins self-
assemble into coiled-coil a-helical heterodimers (Scheibel, 2005), before the 
dimers align antiparallel into tetramers. The stable tetramers are the building 
blocks for higher-ordered hierarchical structures. As a result of the rigid 
structure, keratin is the main constituent of hair, nails, and claws.  
The hitherto mentioned protein materials have mainly biological relevance, 
but are of limited interest from a biotechnological point of view. Still, there are 
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attempts to design nanoscale transport railways with actin and tubulin filaments 
(Knoblauch and Peters, 2004) and to invent novel biomaterials using collagen 
(Cen et al., 2008).  
Contrary, spider dragline silk is ‘natures high performance polymer’ 
(Whitford, 2005) and was for a long time referred to as the strongest biobased 
material. This notion has been challenged by the nanocellulose fibers alluded to 
earlier (Mittal et al., 2018). Still, the potential utilization as a biomaterial, ultra-
strong textiles, and as a functionalized scaffold, has triggered a several decade 
long, world-wide effort in order to understand the material and produce it 
recombinantly (Jansson et al., 2014, Bittencourt, 2016). To date, Adidas and The 
North Face have produced prototypes based on spider silk for light weight 
running shoes and resistant outdoor jackets, respectively (Salehi and Scheibel, 
2018).  
The spider silk protein-based material relies on the ordered assembly of so 
called spidroins. Spidroins are 3 - 4,000 long aminoacid residue chains with a 
distinct N-terminal and a C-terminal domain. Embedded in between these 
domains are tandem repeats of alternating polyalanine blocks and glycine rich 
regions. In a spider, the proteins are stored at a concentration of 50% (w/v) in 
the ampulla. Natural spidroin polymerisation requires gradual extraction of 
water, and the exchange of Na+ and Cl- ions with K+, H+, and PO43-, which 
steadily decreases the pH along the spinning duct. Finally, the silk structure can 
be best described as an arrangement of crystalline antiparallel b-sheet cores, that 
are connected via unstructured regions. Even though this material has a lot of 
biotechnological potential, there are still some challenges that need to be 
overcome. Since the spidroins are extremely long and repetitive proteins, only 
truncated versions can be produced in Escherichia coli (E. coli). In addition, the 
natural silk secretion mechanism has not been completely replicated artificially. 
Instead, other methods are used for fiber formation, such as wet spinning, 
electrospinning, and spinning with microfluidic devices (Rising, 2014). A recent 
breakthrough made it possible to mimic the natural spinning silk conditions, 
which demand a 50% (w/v) spidroin solution that is subjected to a lower pH to 
initiate fiber formation (Andersson et al., 2017). However, these in vitro 
produced materials do not yet possess the superior material properties of the 
natural product (Jannson, 2015, Rising, 2014, Andersson et al., 2017). 
Proteins that do not have an innate inclination to form elongated structures 
can also be utilized for building nanomaterials with specifically tailored 
functions. These structures include, but are not limited to, artificial protein-based 
nanocages using DNA-binding-proteins recruited by gold (Ma et al., 2015) or 
the WA20 dimer, a peptide scaffold for barrels, tetrahedrons, and cubes 
(Kobayashi et al., 2016). These and similar setups can be used in biosensors, 
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biomedical applications, as catalytic nanomaterials, and nanowires (Luo et al., 
2016). 
In general, protein materials are a promising scaffold for supramolecular 
assemblies that could be used in healthcare, since they can be designed from the 
bottom-up, due to their inherent self-assembling properties. In addition, protein 
based materials are biodegradable, and have the ability to mimic native matrix 
elements (Webber et al., 2015). 
The above-named advantages are also true for other types of applications in 
the biotechnological field. Probably the strongest argument to use 
peptides/proteins as composites for nanomaterials is the fact that these complex 
structures are encoded within DNA, which can be easily manipulated and 
specifically designed on a genetic level. The pre-existing cellular machines E. 
coli and K. pastoris make recombinant protein production a routine job, as the 
route from the manipulated DNA to the correctly folded protein is entirely 
executed by the microorganisms (Soto, 2014). 
2.3 Protein Nanofibrils (Amyloid) 
2.3.1 Structure of Protein Nanofibrils 
Protein folding is a complex process and its accurate execution is fundamental 
to enable the correct protein function. The fold is dependent upon the aminoacid 
sequence and is then governed by the hydrophobic effect, electrostatic 
interactions, Van der Waals interactions and assisted by intracellular chaperones. 
The folding pathway guides the unstructured peptide produced by the ribosome 
towards the native state of the globular protein, which occupies a local minimum 
on the energy landscape of protein folding (Figure 1) (Wei et al., 2017). 
Therefore, the native fold is only a meta-stable state, or in other words, a cell has 
to ensure an intact proteome unceasingly by removing misfolded proteins (Chen 
et al., 2011). If this advanced cellular machinery fails, the ultimate fate of many 
soluble proteins is the deposition into highly ordered PNF, which is a sinkhole 
on the energy landscape for protein folds (Adamcik and Mezzenga, 2018, 
Perczel et al., 2007, Toyama and Weissman, 2011).  
Commonly these aggregates are called ‘amyloid’, a name closely associated 
with medical terminology. The reason is that accumulation of these type of 
protein aggregates is associated with some of the most devastating neurological 
and nonneuropathic human diseases. The deposits can occur in vital organs, e.g. 
the brain, the heart, or kidney and destroy healthy tissue. Among others, the 
amyloid aggregates cause Alzheimer disease, Parkinson disease, ATTR-
19 
 
amyloidosis, Huntington’s, or type II diabetes (Chiti and Dobson, 2006). Later, 
I will show that ‘amyloid’ is not only associated with disease, but that amyloid 
in many cases is constitutive for physiological functions. 
From a structural perspective, the ‘misfolded’ proteins, are stacked on top of 
each other to form two or more b-strands, which mainly align in-parallel, and 
in-register (Figure 2) (Luhrs et al., 2005). The b-strands are glued together by 
Figure 1. Energy landscape of protein folding (Balchin et al., 2016). The energy levels for the 
various protein folds is schematically illustrated. The amyloid fold has the lowest possible 
energy, which explains its stability.  
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main chain hydrogen bonding. This arrangement leads to long assemblies of b-
sheets, which in turn are held together by the hydrophobic effect, side chain 
hydrogen bonding, or electrostatic interactions (Nelson and Eisenberg, 2006). In 
the mature fibril, the b-strands are oriented perpendicular to the fiber axis, with 
the consequence that this configuration is referred to as ‘cross-b structure’. The 
structure in Figure 2 has been determined with in vitro formed ab42 fibrils, 
which are normally found in brain deposits of Alzheimer patients. Later studies 
indicate that the ab42 aligns as a more complex fibril dimer, but the common 
characteristics of a cross-b structure still apply (Colvin et al., 2016).  
At this point it is important to note that the difference between other protein 
materials discussed earlier and the amyloid state is that its characteristic 
architecture is not encoded by a specific amino acid sequence (Schleeger et al., 
2013). Instead, the propensity that proteins with, for instance asparagine and 
glutamine rich regions form amyloid fibrils is higher compared to other regions 
(Zambrano et al., 2015). In fact, probably most proteins can coalesce into 
amyloid fibrils if conditions are chosen that promote protein misfolding 
(Stathopulos et al., 2004, Adamcik and Mezzenga, 2018, Maji et al., 2009, Wei 
et al., 2017).   
Figure 2. The basic cross-b structure of an ab42 amyloid nanofibril. During aggregation into 
nanofibrils the individual peptides refold into one or more b-strands that are stacked on top of each 
other. The individual peptides are indicated by different shades of green. The interstrand distance is 
typically 4.7 Å and the intersheet distance is 10 Å. The cartoon structure is derived from the ab42 
structure with the PDB-ID: 2BEG.  
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2.3.2 Functional Amyloid  
The discovery of amyloid that serves an assortment of physiological functions, 
so-called functional amyloid, is a vivid testament of the fact that this material is 
more than just the cause of diseases (Li et al., 2014). For instance, E. coli secretes 
curli proteins, which self-assemble extracellularly into curli fibrils and are 
essential for biofilm formation (Cherny et al., 2005). In the same manner, 
complex multicellular organisms employ amyloid for specific functions. 
Lacewings are insects that protect their eggs with silk that shows a cross-b 
structure (Bauer et al., 2012). Barnacles are marine crustacea organisms that 
produce underwater adhesive amyloid fibrils, which aids the attachment of the 
animals to targeted surfaces (Nakano and Kamino, 2015). Another surprising 
discovery was that the storage of hormones in secretory granules is 
accomplished through their reversible deposition as amyloid fibrils (Maji et al., 
2009). 
These and many other findings commenced a paradigm shift from a view that 
condemned amyloid as a pure pathological entity, to the point that amyloid 
fibrils are recognized as an excellent material in bio-nanotechnology. To 
conclude, I want to emphasize the distinction between ‘functional’ and 
‘functionalized’ amyloid. The very definition of functional amyloid was 
illustrated in the examples above, i.e. amyloid that serves an important 
physiological role. Contrary, functionalized amyloid are engineered PNFs, by 
genetic re-design or similar methods, artificially endowed with a foreign 
functionality.  
2.3.3 Material Properties 
The incentive that functional amyloid is used for a remarkable collection of 
diverse application is the advantageous material properties that are exploited by 
living organisms (Wang et al., 2018, Knowles and Buehler, 2011, Fowler et al., 
2007). Amyloid fibrils are self-assembling and possess a high mechanical 
strength that resembles the properties of spider dragline silk (Knowles et al., 
2007, Knowles and Buehler, 2011) (Table 1). In addition, the fibrils are 
chemically and biologically robust. In particular, they can tolerate heating to 100 
°C, extreme pH, high concentration of denaturants and salt, as well as proteolytic 
degradation (Scheibel et al., 2003, Baxa et al., 2004). Dependent on the 
amyloidogenic peptide the core diameter of the fibrils can be less than 10 nm 
with a length of several µm (Figure 3). Thus, the nanofibrils exhibit an 
extremely large surface area over volume ratio.  
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The biotechnological perspective also appreciates, with respect to the 
material properties, the biocompatibility on account of a minimal immunogenic 
and inflammatory potential (Hauser et al., 2014). Moreover, fibril modifications 
that lead to novel functions can be introduced genetically or by other means. 
Highly amyloidogenic proteins can be truncated, in order to remove domains or 
regions that are not essential for fibrillation. Additional modifications that can 
 
Table 1. Comparison of the Youngs modulus and the ultimate strength of amyloid with other 
materials. 
Material Youngs modulus (GPa) Ultimate strength (GPa) 
Diamond a) 1000  
Steel b) 200 0.6-1.8 
Wood c) 8-15  
Spider Dragline Silk d) 1-10 1-1.5 
Amyloid e) 0.2-14 0.6 
Keratin f) 1-3 0.02 - 0.2 
Rubber g) 0.001-0.01 0.02 - 0.04 
The Youngs modulus measures the elastic elongation of the material under stress. The ultimate 
strength is a measure of the maximal pulling stress necessary to break the material. a) (Savvides 
and Bell, 1992). b) (Chen et al., 2016). c) (Green, 1999). d) (Vehoff et al., 2007, Agnarsson et al., 
2010). e, g) (Smith et al., 2006, Knowles and Buehler, 2011). f) (Bonser, 2000, McKittrick et al., 
2012). 
 
 
Figure 3. TEM image of amyloid fibrils. Amyloid fibrils can be as short as 100 nm or much longer 
than 1 µm. The fibril core typically has a diameter of 5-15 nm. The scale bar indicates 1 µm. 
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be implemented is the re-design of the amyloidogenic peptide sequence and the 
gene fusion to functional domains. The material is environmentally friendly 
produced by microorganisms, which means there is no chemistry involved, not 
even for functionalization. Specific examples of genetic functionalization and 
other types of modifications that are not introduced through DNA will be 
discussed later. 
Another biotechnological relevant property is that the PNFs can be 
manufactured into different macro-morphological structures. The most 
acknowledged examples are threads (Kamada et al., 2017), hydrogels (Loveday 
et al., 2011), aerogels (Nystrom et al., 2016), foams (Peng et al., 2017), films 
(Knowles et al., 2010), and beads (Zhou et al., 2015). 
Even though functional amyloid is widely used in nature, safety concerns for 
in vivo applications are still prevalent (Wei et al., 2017). Apprehensions are 
related to potential cross-seeding effects that could cause undesired, pathological 
protein aggregation in vivo. However, the latest research suggests that the mature 
fibrils are not the cause of toxicity, but instead the fibrillar precursor 
intermediates (Hauser et al., 2014, Cherny and Gazit, 2008). Still, the safety 
concerns cannot be completely disregarded. For instance, when a mouse model 
for AA-amyloidosis was injected with sonicated functional amyloid from E. coli 
and Saccharomyces cerevisiae (S. cerevisiae), the mouse model showed an early 
onset of amyloidosis in the spine (Lundmark et al., 2005). At the same time, 
injection of silk from Bombyx mori also resulted in the formation of early 
amyloidosis in the mouse model. This is not surprising considering that silk is 
structurally extremely similar to amyloid (Cherny and Gazit, 2008). 
2.3.4 Nanofibril Forming Peptides 
The scaffold for the design of new protein nanomaterials is an important choice 
since their properties need to match the application. Factors that might be of 
importance are the charge of the side chains, the hydrophobicity, the fibrillation 
kinetics, the peptide solubility, and the peptide size.  
There is a broad selection of natural and artificial motifs that are innately 
prone to immediate aggregation. Among this selection, the fibril forming 
peptides can be as short as two phenylalanines (Diaz-Caballero et al., 2018, 
Tamamis et al., 2009). Other artificial peptides such as the b-16 that possesses 
amphiphilic properties (Kodama et al., 2004), or the b-tail that aggregates very 
efficiently, were used for functionalization (Hudalla et al., 2014). Natural 
existing alternatives are curli proteins from E. coli (Zhong et al., 2014). The 
SH3–domain dimer from bovine phosphatidylinositol-3-kinase is a good choice 
if the application requires that the fibril assembly is restricted, unless a ‘switch’ 
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is activated (Bader et al., 2006). In the case of the (SH3)2, fibrils do not form if 
the pH is higher than 3. Sometimes, peptides that originate from pathological 
amyloid are functionalized, for example transthyretin (TTR) (Channon et al., 
2008). On account of the still limited understanding of the exact mechanism and 
risk factors that triggers amyloidosis, these peptides are less appropriate for 
biotechnological applications.  
With this in mind and for our purposes, we decided to employ the intrinsically 
unstructured regions from Sup35 and Ure2, that natively form functional 
amyloid in S. cerevisiae (Knowles and Buehler, 2011). The reason for this choice 
was that the two proteins form one of the best characterized functional and 
functionalized amyloids. 
Natively, Sup35 is a translation release factor with 685 aminoacid residues. 
Fibrillation of Sup35 increases the suppression of nonsense mutations, which 
means that there is an increased tendency of the ribosome to read through stop 
codons (DePace et al., 1998). Structurally, Sup35 has three distinct domains. The 
N-terminal domain (1-114) is rich in polar residues (45% glutamine and 
asparagine) and tyrosine (18 %) (King, 2001). The M-domain (115-253) has no 
known function, but is often used to enhance the solubility of the amylogenic N-
terminal domain (Glover et al., 1997). The C-terminal domain (254-685) is 
essential for native functionality. In this work we decided to use a truncated 
version of Sup35(1-61) as the basis for new PNF, since this fragment has been 
successfully used earlier in vivo and in vitro for the same objective (King and 
Diaz-Avalos, 2004, Men et al., 2009). Sup35(1-61) has a molecular weight of 
8,995 kilo Dalton (kDa). 
When correctly folded, the ureidosuccinate transporter Ure2 binds and 
inhibits the protein Gln3, a transcription factor that represses genes involved in 
metabolizing poor nitrogen sources, when easier accessible sources are present. 
Hence, the aggregation of Ure2 in vivo leads to the uptake of poor nitrogen 
sources even if easier accessible ones are available (Baxa et al., 2002). The 
protein has 354 aminoacid residues and possesses two domains. The N-terminal 
region (1-64) of Ure2 is amyloidogenic and rich in asparagine (42%). Truncated 
Ure2(1-64) is sufficient for fibrillation but Ure2(1-80) forms fibrils much faster, 
which is the reason for choosing Ure2(1-80) as an additional scaffold for 
functionalization (Maddelein and Wickner, 1999, Baxa et al., 2002). Our 
Ure2(1-80) construct has a molecular weight of 10,793 kDa. 
There are no known high-resolution structures of Sup35 or Ure2 fibrils 
except for the heptapeptide GNNQQNY fragment from Sup35 (Sawaya et al., 
2007). However, solid-state NMR experiments have shown that Sup35 
nanofibrils have a parallel in-register b-sheet architecture, which agrees with the 
amyloid structure of the ab42 peptide (Gorkovskiy et al., 2014). In addition to 
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the parallel in-register b-sheet structure, electron paramagnetic resonance with 
Ure2 fibrils suggests a hierarchical organization into a super-pleated b-sheet 
structure (Ngo et al., 2011).  
2.3.5 Applications of Protein Nanofibrils: Current Status 
Since the time when amyloids were recognized as a scaffold for self-assembling 
nanofibrils with prospective applications in biotechnology, numerous ingenious 
designs of amyloid materials have been developed. To summarize these designs, 
excellent and comprehensive reviews on functionalized amyloids and 
applications thereof were recently published (Woolfson and Mahmoud, 2010, 
Wei et al., 2017, Wang et al., 2018, Knowles and Mezzenga, 2016, Waku and 
Tanaka, 2017, Hauser et al., 2014, Luo et al., 2016, Díaz-Caballero et al., 2018). 
Here, I want to provide a concise overview.  
Protocols with the aim to create conducting nanowires for potential 
applications in bio-nanoelectronics are based on the idea to use the PNFs as 
templates. For instance, after genetically introducing surface cysteines in Sup35 
fibrils, conductive nanowires were created by reductive deposition of silver and 
gold (Scheibel et al., 2003). Instead of metals, nanowires can also be formed 
with conductive polymers, such as polyaniline. Aniline binds the hydrophobic 
pockets of amyloid b-sheet rich regions. Thus, polymerisation of aniline to 
polyaniline by addition of iron(III)chloride in the presence of lysozyme fibrils 
resulted in a core-shell architecture with good conducting properties (Meier et 
al., 2015). In a similar fashion, nanowires with metallic organic compounds 
utilized in OLEDs were assembled (Elfwing et al., 2015). Another alternative is 
the display of cytochromes on PNFs that natively bind metalloporphyrin 
(Baldwin et al., 2006). 
Enzymatic functionalization of PNFs is a celebrated concept in the literature, 
since enzyme immobilisation on the fibrils can be attained by genetic 
engineering, without the use of post-expression crosslinking chemistry. Among 
the often-cited examples are Sup35 and Ure2 nanofibrils, which were in a proof-
of-concept manner functionalized with alkaline-phosphatase, horseradish-
peroxidase, barnase, carbonic-anhydrase, and glutathione-s-transferase (Zhou et 
al., 2014, Baxa et al., 2003, Baxa et al., 2002, Zhou et al., 2015). Alternatively, 
the immobilisation of enzymes, for instance a-amylase, can also be mediated 
through a binding domain displayed on E. coli amyloid (Nussbaumer et al., 
2017).  
Certainly, it is also possible to chemically crosslink enzymes to the fibrils 
after their formation (Raynes et al., 2011). For example, chemical 
immobilization of enzymes to PNFs was applied to assemble an antibacterial 
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film. Glucose oxidase, which oxidizes glucose to gluconolactone and reduces O2 
to H2O2, was crosslinked to insulin fibrils and embedded in a poly(vinyl alcohol) 
film (Pilkington et al., 2010). In this setup the accumulation of H2O2 acted as an 
anti-microbial agent against E. coli.  
Genetic manipulation of amyloid was likewise implemented to endow curli 
fibrils with underwater adhesive properties (Zhong et al., 2014) and to assemble 
multicomponent fibrils that display three different fluorescent proteins (Hudalla 
et al., 2014). The rational design of heptapeptides that form amyloid fibrils 
resulted in amyloid material that can capture CO2 and, in a different design, 
triples the efficiency of retroviral transduction of human cells (Li et al., 2014). 
A thrilling development of functionalized amyloid materials is the production 
of bio-inorganic hybrid materials. For instance, lysozyme fibrils in combination 
with activated porous carbon acted as water purification filters that could capture 
toxic heavy metal ions from water solutions (Bolisetty and Mezzenga, 2016). In 
an effort to exploit the hydrogel forming properties of β-lactoglobulin fibrils with 
the pH-responsiveness of carbon nanotubes has led to a hybrid material that 
reversible forms hydrogels (Li and Mezzenga, 2012). 
To exploit the biocompatible and biodegradable properties of amyloid, 
biomaterials are developed that can be used for tissue engineering (Holmes et 
al., 2000) and targeted drug delivery (Koutsopoulos et al., 2009). Moreover, 
amyloid fibrils can be valuable to improve diagnostic tools by enhancing the 
sensitivity of immunoassays (Men et al., 2016).  
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3.1  Fibrillation 
The most fundamental concept that leads to meaningful research of 
functionalized PNFs, is a reliable and reproducible method for fibrillation that 
yields fine dispersed fibrils, when the aggregation has finished. Tuning the 
fibrillation to the desired outcome, means to reach complete aggregation of the 
soluble protein, with the result of elongated fibrils that form relatively fast (less 
than 24 h). This task requires some screening in order to identify optimal 
fibrillation conditions. 
The highly complex aggregation kinetics involve several steps and 
aggregation species, starting from nuclei, oligomers, to protofibrils, before the 
mature fibrils are formed. In addition, off-pathway intermediates, such as 
amorphous aggregates can occur, which adds additional complexity to the 
reaction. A fibrillation experiment with soluble amyloidogenic proteins in the 
presence of thioflavin T (Tht), a dye that becomes highly fluorescent at 482 nm 
(excitation 450 nm) when it binds to b-sheet rich regions, shows a sigmoidal 
increase of the fluorescence over time. As a consequence, three phases of fibril 
formation can be distinguished (Figure 4) (Arosio et al., 2015). The absence of 
mature fibrils is distinctive in the beginning of the lag phase, during which no 
increase of Tht fluorescence is observed. The starting point for fibril elongation 
in a true monomeric solution, is primary nucleation, a spontaneous event, which 
is dependent on the monomer concentration and commences on non-fibrillar 
surfaces (Michaels et al., 2018). As soon as primary nucleation has occurred, the 
fibril is elongated by monomer addition (Collins et al., 2004). When enough 
fibril mass has formed, the nucleation event becomes a self-propagating 
mechanism. The secondary nucleation event is catalyzed by the surface of the 
amyloid fibril, and is therefore dependent on the total fibril surface area, and the 
3 Methodology 
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monomer concentration (Meisl et al., 2014). Secondary nucleation accelerates 
the recruitment of monomers, and is one of the main events during the elongation 
phase when Tht fluorescence increases rapidly. In addition to secondary 
nucleation, fibril fragmentation creates additional ends, which makes the 
consumption of soluble monomers faster, but this event has no influence on the 
rate of secondary nucleation. Once the monomers of the sample solution are 
Figure 4. Aggregation kinetics of protein nanofibrils. (A) Together with the dye thioflavin T (Tht), 
the growth of PNFs from a monomeric sample can be observed using a spectrofluormeter (blue 
lines, six replicates). The sigmoidal curve shape of fibril formation indicates three phases. During 
the lag phase the fluorescence is constant at zero. Primary nucleation spontaneously occurs before 
fibril elongation is initiated. During the elongation phase the Tht fluorescence increases rapidly, 
due to secondary nucleation events. The increasing fibril surface area serves as a catalyst that 
promotes the formation of secondary nuclei. As the aggregation progresses, long fibrils are 
fragmented, which creates new ends for monomer addition. When the monomers are depleted, the 
reaction reaches the stationary phase, when fibril elongation and dissociation are in equilibrium. 
(B) Illustration of the different events that occur during fibrillation. 
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depleted, the reaction reaches a stationary phase, when fibril elongation 
thorough monomer addition and dissociation is in equilibrium.  
The large number of events that take place during fibril formation, explain 
the fact that fibrillation can be influenced by several extrinsic chemical and 
physical factors in vitro. Furthermore, the alteration of the conditions does not 
only influence the aggregation kinetics itself but also the fibril morphology, 
which is different for each amyloidogenic protein.  The single most used factor 
that controls fibrillation time, is the concentration of the monomer in the sample 
solution (Hellstrand et al., 2010). Other factors that impact the fibrillation 
kinetics is seeding (DePace et al., 1998), sonication (Chatani et al., 2009), pH 
(Giri et al., 2007), temperature (Sabate et al., 2012), salt concentration (Klement 
et al., 2007, Abelein et al., 2016), agitation (Cohen et al., 2013), or the addition 
of denaturing agents such as urea or sodium dodecyl sulfate (Khan et al., 2016). 
By carefully choosing the fibrillation conditions the morphology can be 
controlled to some degree, but there are no general rules that are valid for all 
amyloidogenic proteins. Another consideration is that care must be taken if the 
aim is to assemble, long fibrils, since they will be fragmented by agitation, 
sonication, and long-time storage (Collins et al., 2004, Ngo et al., 2011). 
3.1.1  Fibrillation Methods in the Literature 
The complexity of the fibrillation kinetics, and the variety of conditions that can 
be chosen during fibrillation generate various options to influence fibril 
formation. Here, I want to focus this discussion on the conditions that have been 
used in the literature for functionalization of PNFs. Above all, I want to highlight 
the diversity of fibrillation protocols, with respect to the yeast prion proteins 
Sup35 and Ure2. 
To functionalize PNFs there are two options. The first option is to use 
chemical conjugation, which is mainly used to create hybrid materials between 
PNFs and other nanostructures (Wei et al., 2017). The second option is to 
fibrillate chimeric proteins, or in other words a fusion variant of the protein 
domain that is prone to assemble into nanofibrils, which will be referred to as 
the carrier protein, and a functional domain. The functional domain is tethered 
to the carrier protein via a peptide linker through genetic engineering and can be 
an enzyme or a protein that possesses an affinity for other biomolecules. After 
expression in the host of choice and purification of the chimeric protein, the 
protein is fibrillated (Figure 5). This strategy to functionalize amyloid fibrils has 
successfully been used numerous times and does not require the use of 
chemicals, which is, from an environmental perspective of importance on large 
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scales. Another strong suit of this technique is the homogeneity of the 
immobilized active domains displayed on the PNFs. The functional domain is 
always linked unidirectionally, either via the N-terminal or the C-terminal end, 
which ensures an optimal orientation. Contrary to this, traditional enzyme 
immobilization techniques rely on a heterogenous chemical attachment to the 
target surface. 
At this point it is worth noting that fibrillation using chimeric proteins only 
(protein fusions of an amyloidogenic carrier with a functional domain), is often 
accompanied by a reduced functionality. This effect is especially severe for 
enzymes, and probably originates from the close proximity of one functional 
domain to the next on the fibril (Wang et al., 2018). Although the peptide linker 
provides some flexibility, large enzymes are still aligned very tightly, which 
consequentially limits the accessibility of the substrate to the active site. A 
Figure 5. Illustration of the fibrillation of a chimeric protein, a fusion variant of the carrier-peptide 
(green), which is intrinsically unstructured, and the functional domain (grey). Through fibrillation, 
functionalized nanofibrils are obtained that display the functional domain on the surface of the 
fibril. The dense alignment of the functional domain may lead to steric restrictions, on account of 
the reduced accessibility of the binding pocket or the active site. The figure is a modelled structure 
using the fibril backbone from ab42 (PDB code: 2BEG) and the enzyme xylanase A from Bacillus 
subtilis (PDB code: 2Z79). 
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fibrillation strategy that could solve this limitation using a mixture of chimeric 
proteins and carrier domain proteins will be discussed in the next section. 
The conditions to assemble PNFs using chimeric proteins based on Sup35 or 
Ure2 can differ quite substantially, but is often carried out at physiological pH 
in a 20 mM NaPi or tris buffer, containing 200 mM NaCl (Baxa et al., 2011). 
The temperature for fibrillation can be in range from 4 to 30 °C (Baxa et al., 
2011, Zhou et al., 2014, Baxa et al., 2002), either with or without shaking (Zhou 
et al., 2014, Baxa et al., 2011). To accelerate the fibrillation of chimeric proteins, 
seeds created by sonication or agitation can be added to monomeric solutions 
(Men et al., 2010, Scheibel et al., 2003). The time it takes until the fibrils are 
mature for harvest is method dependent and can vary from 10 minutes to 3 weeks 
(Men et al., 2010, Baxa et al., 2002). Also, the protein concentration allows 
flexibility and is typically in the range of 0.1 – 2 mg/ml (Baxa et al., 2002, Baxa 
et al., 2011). Unfortunately, these studies do not report condition depending data 
published on the completeness of the fibrillation, i.e. the fraction of monomers 
that were incorporated into the fibril before reaching the stationary phase. 
However, I can refer to the (SH3)2-Cytochrome C chimera which fibrillates with 
70-90% conversion efficiency (Baldwin et al., 2006).  
3.1.2 Fibrillation in this Work 
On account of the steric restrictions that originate from a too dense packing of 
the functional domains on the fibril formed by chimeric proteins, we developed 
a fibrillation protocol that ensures enough accessible space. Instead of 
fibrillating the chimeric protein alone, we applied a strategy of co-fibrillation. 
The basis of this strategy is that the chimeric protein is simultaneously fibrillated 
with the amyloidogenic carrier-protein (Figure 6). To initiate the fibrillation a 
small fraction of the soluble carrier proteins Sup35(1-61) or Ure2(1-80) is briefly 
sonicated in an ultrasonication bath or with a sonicator for cell lysis, to create 
fibril seeds. The sonicated carrier proteins are then immediately added to a 
solution that contains pre-mixed carrier and chimeric protein. Subsequently, the 
fibrils are allowed to form by over-night incubation at room temperature, in a 
sterile 1.5 mL Eppendorf vial. To be able to refer to a specific fibril composition 
independent of the concentrations used during fibrilization we defined the term 
‘doping frequency’, which is the molar ratio of carrier protein over chimeric 
protein.  
This strategy yields a fine-tuned nanofibril assembly, where the carrier 
proteins act as spacers (Paper I and Paper II). Especially functional domains that 
bind large proteins could benefit from this protocol, as steric restrictions are 
avoided. Furthermore, enzymes displayed on PNF could completely retain their 
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functionality as their active site is not shielded by a neighbouring biocatalyst. 
We used this functionalization approach in all of our papers (I – IV). 
In principle this type of co-fibrillation has been reported in previous studies, 
but with the perspective to create a fibril array of multiple functionalities. In 
2004, Kodama et al. reported that fibrillated biotinylated and un-biotinylated 
peptides were co-fibrillated. The significance of this setup was that the co-
fibrillation yielded a regular incorporation of the biotinylated peptide into the 
mature fibril (Kodama et al., 2004). Another report, published 10 years later, 
describes the assembly of a multifunctional fibril, which Kodama et al. 
suggested. In this case three fluorescent proteins (green, blue and red 
fluorescence), were displayed on an amyloid fibril at different ratios. The final  
fibrillar product possessed a distinct fluorescence that corresponded to the 
relative amount of each fluorescent protein in the fibril (Hudalla et al., 2014). 
However, in both instances, the notion that the carrier proteins can be used to 
ensure accessible space for the functional domains was not considered. 
Figure 6. Co-fibrillation of the amyloidogenic carrier proteins (green) and chimeric proteins, a 
fusion variant of the carrier and the functional domain (grey). The doped nanofibril displays the 
functional domain on the surface of the fibril. The carrier proteins that are not linked to a functional 
domain act as spacers to ensure optimal accessibility to the functional domain. 
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3.2 Fibril Characterization 
Once the fibrils were assembled, they were characterized at least with respect to 
the completeness of fibrillation reaction and their morphology. Certainly, the 
fibril functionality was also part of the characterization process.  
After incubation of the seeded sample containing the carrier and the chimeric 
proteins the success of the fibrillation was assessed. To this end, the absorbance 
of the supernatant after centrifugation of the fibril containing sample was 
carefully measured, to determine the concentration of the non-fibrillated 
proteins. Alternatively, polyacrylamide gel electrophoresis (SDS- PAGE) was 
used to compare the protein content of the fibril suspension with the supernatant 
after centrifugation. This information was of particular importance to be able to 
calculate the catalytic constants of the enzymes displayed on the protein 
nanofibrils.  
The fibrils were always imaged using transmission electron microscopy 
(TEM) in order to distinguish between amorphous aggregates and protein 
nanofibrils. In addition, the TEM images provided morphological information 
such as fibril length and width.  
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4.1 Aims of this Thesis 
In general, the aim of this work was to aid the maturation of the functionalized 
PNF technology. Biotechnological utilization of the PNFs has several 
challenges, which require optimization of current protocols for fibril assembly 
and a better understanding of the material. This thesis addresses three of the key 
construction sites and provides a groundwork for additional efforts to develop 
PNF technology. In particular, the present studies aimed to: 
 
Ø Establish a set of applications to stress the versatility of the amyloid 
scaffold and the concept of a tuned doping frequency in co-fibrillation. 
The functionalities should be characterized in detail, i.e. quantitatively 
and not only qualitatively. 
 
Ø Develop a new protocol for PNF assembly that ensures an optimized 
display of the functional domains on the surface of the fibrils.  
 
Ø Design a generic microbial protein production method that is scalable and 
can be used to produce functionalized nanomaterials in a way that requires 
minimal downstream processing. 
 
 
 
 
 
 
 
4 Results and Discussion 
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4.2 Functionalized Materials Developed in this Work 
We were especially attentive to develop PNF materials that are of 
biotechnological relevance with positive practical implications to problems that 
await new solutions.  A summary of the functional domains tethered to Sup35(1-
61) and Ure2(1-80) nanofibrils are found in Table 2.  
Initially, we functionalized Sup35(1-61) and Ure2(1-80) PNFs with a Z-
domain dimer (ZZ) (Paper I and Paper III, Figure 7). The Z-domain is an 
engineered variant of the B-domain, which is part of protein A from 
Staphylococcus aureus. The domain is small (6.6 kDa), has a stable fold, and 
binds several isoforms of immunoglobulin G (IgG) with an equilibrium 
dissociation (KD) in the low nM range. In addition, the Z-domain is also the 
starting point to create affibody molecules, small alternatives to the 150 kDa 
antibodies, through in vitro directed evolution. By displaying ZZ on the PNFs 
we sought to exploit the large surface area over volume ratio of the PNFs. The 
objective was to create an antibody binding nanofibril, with a high IgG binding 
capacity that could compete with other affinity matrices, such as protein A 
Sepharose (GE Healthcare). 
Contrary to Paper I & III, we focused on the concept of enzyme 
immobilization in Paper II & IV. Immobilizing enzymes on PNFs has been done 
several times before, and it is not more complicated than genetic fusion of the 
carrier protein to the functional domain. To make things even simpler the 
complete gene can be purchased directly and ligated into the vector of choice, 
before it is expressed in E. coli and purified by chromatographic methods. 
With respect to enzymes the biggest restraint is to find suitable candidates. 
In principle all enzymes can be excluded, except those that are active as a 
monomer. Many enzymes are dimers or possess even more complicated tertiary 
structures, which makes the production of chimeric proteins difficult. If no 
alternatives exist, genetic dimer fusions may mimic a monomer, but the 
construction of such an ensemble could be time consuming. Other properties that 
need to be considered when choosing enzymes for PNF functionalization is the 
long-term stability, availability of co-factors, and any requirement for auxiliary 
proteins. For our purposes we also preferred that the functional entities are 
soluble and expressible in E. coli. 
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In Paper II we immobilized the β-Lactamase TEM1 from E. coli on Ure2(1-
80) fibrils (Figure 7). The enzyme hydrolyzes β-lactam antibiotics such as 
penicillin and ampicillin and could be a valuable tool to ensure that antibiotics 
are not released into the environment. We specifically chose to study the kinetics 
of this enzyme because it has a kcat/KM that is close to the limit of diffusion. 
In Paper IV, we advanced the concept of enzyme functionalization one step 
further and designed an entire reaction cascade build from three enzymes 
(Figure 7). We combined xylanase A (XynA) from Bacillus subtilis (Bourgois 
et al., 2007), β-xylosidase (βXyl) from Caulobacter crescentus (Correa et al., 
2012), and an pyrroloquinoline quinone dependent aldose sugar dehydrogenase 
(ASD) from E. coli (Southall et al., 2006) to hydrolyse and oxidize the 
polysaccharide xylan into xylonolactone. 
 
Table 2. Functionalized materials demonstrated in this work. 
Fusion protein Application Paper 
Z-domain dimer Antibody purification and immunoassay I & III 
β-Lactamase Penicillin degradation II 
Carbohydrate processing enzymes Processing biomass IV 
Figure 7. Protein constructs in this work. The histidine tag (His6) was used for protein purification. 
The abbreviation TS refers to a thrombin cleavage site. To link the carrier and the functional domain 
a GGGGSG peptide was used. 
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4.3 Sup35(1-61) and Ure2(1-80) 
The truncated carrier proteins Sup35(1-61) and Ure2(1-80) were expressed in E. 
coli, but accumulated as insoluble inclusion bodies during cultivation. 
Therefore, we used 8 M urea, to solubilize the inclusion bodies and subsequently 
purified the proteins with immobilized metal ion affinity chromatography 
(IMAC) followed by ion exchange chromatography (IEX). The production yield 
of a 1 L E. coli culture varied for both proteins from batch to batch, but was in 
the range of 5-20 mg/l after IMAC purification. The two carrier proteins had to 
be flash frozen and stored in 8 M urea at -80 °C, and were stable for at least one 
year after purification. Higher temperatures (-20 °C) were not appropriate for 
storage, since aggregates formed immediately when the protein solution was 
thawed. We were also careful to reduce the sample handling time at room 
temperature as much as possible. Matrix assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS) experiments have shown 
that almost one half of Sup35 is carbamylated already after 48 h in 8 M urea 
(Figure 8).  
The lag time for Ure2(1-80) (5 µM) and Sup35(1-61) (5 µM) at 37 °C (100 
rpm) is on average 5.7 h and 13.8 h, respectively, which implies that Ure2(1-80) 
Figure 8. MALDI-TOF MS of Sup35(1-61) stored in 8M urea for 0, 2, 7, and 30 days. In the 
beginning of the storage the protein has a mass of 8995 Da, but during storage the N-terminal end 
is carbamylated and gains 43 Da. After 30 days of storage, all protein is carbamylated. 
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fibrillates faster (Figure 9A).1, 2 Using identical conditions, we also co-
fibrillated 5 µM Sup35(1-61) with 0.25-5 µM Sup35(1-61)-ZZ (Figure 9B). 
Addition of the chimeric protein to the carrier protein shortened the lag time by 
a factor of three. On the contrary, the lag time was either not influenced or 
extended when 5 µM Ure2(1-80) was co-fibrillated with TEM1-Ure2(1-80) in 
the range of 0.02-0.5 µM (Figure 9C). Even if the effect is more severe for 
Ure2(1-80), the common denominator in both setups is that higher concentration 
of chimeric protein renders a lower fluorescence amplitude in the stationary 
                                                        
1. This is only valid for a black 96 well Nunc X180 Microplate (Polystyrene, Thermo Scientific) 
covered with Nunc X100 sealing tape (Thermo Scientific). The sample volume was 100 µl in a 10 
mM KPi buffer containing 150 mM NaCl, 50 µM ThT, at pH 7.4. 
2. It is not possible to compare these values with already published data to draw conclusions for 
two reasons. (1) Most reports discuss fibrillation of Sup35(1-254). (2) There is no standard protocol 
in the preparation and fibrillation of Sup35, as it is the case for ab42.  
Figure 9. Tht fibrillation assay. (A) Fibrillation of 5 µM Ure2(1-80) (blue) and 5 µM Sup35(1-
61) (green) at 37 °C and 100 rpm in quintuplicates. (B) The same conditions as in (A) but in this 
case 0, 0.25, 0.5, 1, 2.5, or 5 µM Sup35(1-61)-ZZ (in the same order dark to light-green) was added 
to 5 µM Sup35(1-61). (C) The same conditions as in (A). Here, 5 µM Ure2(1-80) were fibrillated 
together with 0, 0.02, 0.05, 0.1, 0.2, and 0.5 µM TEM-Ure2(1-80) (in the same order dark to light-
blue). The fibrillation curves in (B) and (C) are averages of six replicate experiments. The data 
shown here is not published.  
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phase. This indicates that only a fraction of the carrier and chimeric proteins are 
fibrillated.  
Recovery of the fibrils formed in the 96-well plates proved to be extremely 
difficult since they were inseparable from the polystyrene surface. Since the 
ultimate aim was not to study the fibrillation kinetics, but to assemble doped 
nanofibrils for enzyme and binding kinetic characterizations, we moved from 
the 96-well plate to Eppendorf tubes (polyethylene). The results from our initial 
co-fibrillation experiments suggested that it is difficult to co-fibrillate using 
higher amounts of chimeric proteins. Therefore, we developed a new fibrillation 
protocol that would yield complete fibrillation of both the carrier and chimeric 
proteins. The best results with respect to complete fibrillation were achieved 
when a small portion of soluble carrier protein was sonicated to create seeds. 
After sonication the seeds were added immediately to an Eppendorf vial, 
containing pre-mixed chimeric and carrier protein. The mature functionalized 
fibrils formed during overnight incubation.3 
 Another essential characteristic of the carrier proteins, which we verified 
was whether or not they restrain the functional domain of a chimeric construct. 
To elucidate this inquiry, the binding rates for the Z-domain dimer linked to 
Ure2(1-80) and Sup35(1-61) was determined with a surface plasmon resonance 
(SPR)-assay (Table 3). As a reference served the Z-domain without a tag, with 
the result that the carrier protein has no effect on ZZ. Likewise, the functionality 
of the enzyme-carrier protein chimeras was characterized by determination of 
the Michaelis-Menten constants (kcat and KM) and compared to literature values, 
where available. In the same way we concluded that the carrier protein tag has 
no effect on the activity of linked enzymes, at least in the case of TEM1 and 
βXyl.  
We think that the discrepancy between the kcat values of ASD is not due to 
enzyme inhibition by the Sup35 tag, but rather due to calculation errors in the 
reference paper (Southall et al., 2006). The enzyme assay is based upon the 
oxidation of xylose to xylonolactone in the presence of 2,6-dichloroindophenol 
(DCIP), which is simultaneously reduced (Dε600 = 21 mM-1 cm-1). According to the 
materials and methods section the enzyme assay was executed as follows: The 
reduction of 50 µM DCIP was recorded for 150 s with a spectrophotometer, in 
the presence of 100 mM glucose and 1-8 µg enzyme, in a 1 mL cuvette. From 
Figure 3 in the reference paper we know that the enzyme activity was at least 
400 U at pH 8.75, were 1 U is defined as 1 µmol/(min mg). Thus, in this specific 
assay, 5 µg enzyme (from Figure 3 in the reference paper) should be able to 
oxidize glucose, and likewise reduce DCIP, at a rate of 2 µmol/min. Considering 
that DCIP amount in the cuvette was 50 nmol, the dye would have been 
                                                        
3. Experimental data is found in the Supporting Information of Paper I and Paper II 
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consumed within 1.5 seconds, which makes it impossible to follow the reaction 
for 150 s, as stated in the material and methods section. Obviously, the authors 
made some serious errors in their activity measurements, which undermines the 
credibility of the reported kcat value. Unfortunately, we were not able to find 
other reports for the catalytic efficiency of ASD from E. coli in the literature. 
However, another monomeric ASD from the thermophilic organism 
Pyrobaculum aerophilum has a kcat of 3.2 s-1 (Sakuraba et al., 2010), which 
agrees well with the kcat value determined in Paper IV.  
 
4.4 The Concept of Doped Nanofibrils 
In several works that functionalize nanofibrils by genetically and chemically 
linking enzymes to the amyloidogenic carrier proteins (see Figure 5) a severe 
reduction of the catalytic efficiency is observed (Baxa et al., 2002, Zhou et al., 
2014, Wang et al., 2018, Pilkington et al., 2010, Raynes et al., 2011). We 
speculated that the proximity of one functional domain to the next is the main 
factor that contributes to this effect, as dense packing could lead to shielding of 
the active site/binding site of a functional domain. The main objective of Paper 
I was to elucidate whether or not this hypothesis is true. In Paper II we sought to 
 
 
Table 3. Binding and catalytic constants of Sup35(1-61) and Ure2(1-80) tagged functional 
proteins are compared with reference values. 
soluble chimeric protein kon (M-1s-1 x 105) koff  (s-1 x 10-4) 
Sup35-ZZa 3.8 / 2.4 1.0 / 3.4 
ZZ-Ure2a 4.2 / 2.4 0.7 / 3.4 
   
soluble chimeric protein kcat (s-1) KM (µM) 
TEM1-Ure2b 1396 / 1428 41 / 50 
βXyl-S35c 21 / n. a. 7.4 / 9.3 
Sup35-ASDd 5 / 3360 382*103 / 400*103 
The experimental values are compared to reference values in the format ‘experimental / 
reference’. a) Experimentally determined binding constants to IgG are compared to binding 
constants for the untagged Z-domain (Paper I). b) Experimentally determined catalytic constants 
(Paper II) are compared to literature values using the substrate ampicillin. c) The catalytic 
constants are reported in Paper IV. No reference value for kcat for this particular enzyme was 
reported in the literature (substrate: pNP-X). d) Experimentally determined catalytic constants 
from Paper IV with xylose as the substrate. The KM value are comparable to values from the 
literature but kcat (glucose) is apparently 1,000-fold reduced. An explanation can be found in the 
text. 
 
 
42 
 
confirm that the functionality of TEM1 with a catalytic efficiency near the limit 
of diffusion is completely retained when it is displayed according to our 
functionalisation-hypothesis. Even if this hypothesis is not discussed in Paper III 
and IV, fibrillation to assemble functionalized fibrils was carried out according 
to the same protocols. 
In Paper I we decorated Sup35(1-61) and Ure2(1-80) nanofibrils with the Z-
domain dimer by simultaneous fibrillation (see the concept in Figure 6) of the 
carrier protein and the chimeric proteins (Figure 7). The Z-domain dimer was 
an ideal candidate for the purpose of testing the functionalization-hypothesis as 
it is a small domain that binds IgG, which is 15 times larger. An optimal point 
for functionalization should become evident by determination of the IgG binding 
capacity as a function of the doping frequency. Therefore, we assembled a set of 
fibrils with a doping frequency between 1:0.04 and 1:0.65 for Sup35(1-61) and 
in the range of 1:0.04 to 1:0.9 for Ure2(1-80) fibrils. The binding capacity of 
human IgG for each fibril was determined in six experimental replicates. In this 
experiment, we found evidence that supports our hypothesis, since we 
demonstrated that both fibril scaffolds have indeed an optimal ratio of carrier 
over chimeric protein. The best doping frequency was 1:0.33 (binding capacity 
1.8 mg IgG /mg fibril) and 1:0.49 (binding capacity 1.7 mg/mg), for Sup35(1-
61) and Ure2(1-80) fibrils, respectively (Figure 10A, D). A higher doping 
frequency above these points reduced the functionality significantly (Figure 
10C, F). For instance, IgG occupies 60% of all possible Z-domain dimer binding 
sites in a 1:0.33 Sup35-fibril but only 40% if the doping frequency is 1:0.65. The 
same relationship is also true for Ure2 fibrils. Furthermore, it is interesting to 
note that our data confirms that the IgG molecules require a minimum amount 
of space along the fibril. The antibodies claim on average 6.5 fibrillated 
Sup35(1-61) proteins and 5.8 Ure2(1-80) proteins (Figure 10D, E), which 
corresponds to 3-3.5 nm fibril length (Figure 2). This number is constant for 
doping frequencies above 1:0.49 and indicates that an even tighter arrangement 
of antibodies is not possible. Thus, any additional ZZ-domains are inaccessible 
and lower the binding capacity.  
Inspired by these findings, we verified if the catalytic efficiency of TEM1 on 
Ure2 fibrils is reduced by steric restrictions if we equip the fibrils with a low 
enzyme density (Paper II). First, we determined the kcat and KM of fibrils with a 
doping frequency in the range of 1:1*10-3 to 1:30*10-3. These initial results 
showed a severe reduction of kcat by a factor of 10 compared to the soluble 
protein. The reduction of kcat was independent of the doping frequency. Contrary 
to this observation, the KM is linearly increased with the doping frequency, which 
indicates mass transport limitation. Therefore, to determine the actual maximal 
turnover rate we mounted the fibrils in a flow reactor, to be able to deliver the 
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substrate to the enzyme by flow and not by diffusion. In this setup we determined 
that the maximal rate of hydrolysis of TEM1 immobilized on the PNFs is 1122 
s-1, which corresponds to 80% of the soluble enzyme (Table 3). In conclusion, 
these results serve as a further evidence that supports our functionalization-
hypothesis.  
 
Figure 10. Optimized doping frequency of Sup35(1-61) and Ure2(1-80) nanofibrils (Paper I). The 
left-hand panel shows data for Sup35 fibrils and the right hand-panel refers to Ure2 fibrils. (A & D) 
The IgG binding capacity of ZZ-domain doped nanofibrils is plotted as a function of doping 
frequency (molar ratio of carrier over chimeric protein). (B & E) The number of fibrillated 
monomers that are necessary to bind one antibody. (C & F) Linear dependency of the theoretical 
binding capacity (assuming that all ZZ-dimers bind one molecule IgG) as a function of the ZZ-
domain doping frequency. The figure was reproduced with the permission from the publisher. 
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4.5 Enzyme Kinetics of Functionalized Nanofibrils  
4.5.1 Kinetic Model for Enzymatically Endowed Nanofibrils         
Trapped in a Column 
So far, reports of enzymatic functionalisation of PNF in the literature have 
been limited to a qualitative level. New functional endowments are presented 
in a proof-of-concept manner, where kcat as well as KM of the fibrils are 
reported, but additional kinetic characterizations are missing (Zhou et al., 
2014). In addition, speculations that mass transport, steric restrictions or both 
are the cause for a severe reduction of enzymatic efficiency have not been 
further investigated.  Nevertheless, an answer to this issue is constitutive, for 
the development of biotechnological applications. Therefore, in order to go 
beyond the simple qualitative stage, we trapped Ure2 fibrils that display TEM1 
in a microcolumn (Paper II). In this setup, fibrils with a doping frequency of 
1:3*10-3, 1:6*10-3, 1:12*10-3, and 1:30*10-3 were embedded between two 0.45 
µm filters. The filters were important to avoid premature contact of the enzyme 
with the substrate solution containing ampicillin, which was forced through the 
column by centrifugation. The amount of hydrolysed ampicillin after passing 
through the layer of TEM1 functionalized fibrils was determined by measuring 
the absorbance at 235 nm (Dε235 = 900 M-1 cm-1). Together with the flow rate, 
we were able to calculate the number of hydrolysed substrate molecules per 
enzyme each second as 
 
 
where Q is the flow rate V/∆t, E&'& the total enzyme amount (mol), and ∆[S] the 
difference of the substrate concentration after fibril passage. This expression was 
related to the total number of available substrate molecules per enzyme each 
second. To explain the data, we re-derived the Michaelis-Menten equation with 
the assumption that the flow, rather than diffusion transports the substrate to the 
enzyme. Here, we obtained an equation that resembles the Michaelis-Menten 
equation 
 
r0		=	k2 1 [S][E]tot QVR[S][E]tot QVR +KM,flow<	
 
(2.) 
Δ[S]QE&'&  (1.) 
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where r0 is the rate of product formation per enzyme,	k2 the maximal substrate 
turnover rate, [E]&'& the total enzyme concentration in the reaction volume V>. K?,@A'B can be interpreted as the number of substrate molecules available per 
enzyme each second in order to reach ½ k2. Since the reaction volume (the 
volume of the fibril layer) cannot be easily determined, we multiplied [E]&'& with V>, which yields  
 [S][E]tot QVR =		[S]QEtot 	 (3.) 
Classically, the Lilly-Hornby equation is used for the purpose of characterizing 
an immobilized enzyme, in a flow reactor (Urban et al., 2006). To be able to fit 
the enzyme kinetic data to the Lilly-Hornby equation, the converted substrate 
amount after column passage is determined for four (or more) flow rates, as a 
function of substrate concentration (Seong et al., 2003). The model yields two 
parameters. The reactor capacity C is only valid for the specific enzyme amount 
immobilized in the flow reactor and is reported for all flow rates. The same 
applies to the (apparent) substrate concentration KM(app) when the biocatalyst 
reaches half of the maximal turnover rate.  
Since centrifugation of our microcolumn was not able to yield an identical 
substrate flow rate every time, we had to choose an unconventional approach 
and plotted our data as Δ[S]QE&'&CD over [S]QE&'&CD. Altogether, 35 measurements of 
the catalytic fibrils with four different TEM1 doping frequencies merged into a 
hyperbolic curve (Figure 11). The data was fitted to equation (2.) with the result 
that the maximal turnover rate of TEM1 displayed on Ure2(1-80) is 1122 s-1. 
Notably, the rate constant is indeed almost identical to the kcat of the soluble 
enzyme. Therefore, the origin of the reduced catalytic efficiency of the TEM1 
functionalized fibrils in suspension can only be explained by mass transport 
limitations and not steric restrictions. 
To validate our model further, we tested if equation (2.) can be used to fit 
data from previous publications that relied on the Lilly-Hornby equation. To this 
end, we converted the data from several articles to Δ[S]QE&'&CD over [S]QE&'&CD. In 
Figure 12 we have chosen to include a representative collection which includes 
data from the original paper published by Lilly and Hornby (Figure 12C & D) 
and other more recent studies (Figure 12A & B) (Lilly et al., 1966, Mansfeld 
and Schellenberger, 1987, Matosevic et al., 2011). Figure 12A & B strongly 
indicate that equation (2.) is not only valid for the TEM1-Ure2(1-80) fibril 
reactor, but generally applicable. Moreover, the data plotted in Figure 12C & D 
fits rather poorly to equation (2.), but the overall trend still suggests a hyperbolic 
dependency. In conclusion, instead of reporting the column capacity C and an 
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apparent KM(app), which has limited meaning for comparison purposes, our new 
model makes catalytic columns extremely comparable. Equation (2) yields two 
constants, k2 and KM,flow that are independent on flow rate and enzyme 
concentration. These constants can be used in the same way as kcat and KM are 
used to characterize enzymes.  
  
 
 
 
 
 
 
 
 
 
 
Figure 11. The number of substrate molecules hydrolysed by each enzyme each second as a 
function of the total number of substrate molecules that encounter each enzyme each second. 
The hydrolytic events were measured with TEM1 functionalized fibrils with doping frequencies 
of 1:3*10-3 (blue), 1:6*10-3 (green), 1:12*10-3 (red), and 1:30*10-3 (black), trapped in a 
microcolumn. This data was fitted to equation (2., dashed line), which yielded the constants k2 
(maximal substrate turnover rate) and KM, flow  ([S]QEtot-1 at ½  k2). 
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4.5.2 A Cascade Reaction Catalysed by Three Enzymes       
Immobilized on Nanofibrils 
Enzyme immobilization using amyloid fibrils is a well-established method, 
which was already demonstrated using several different biocatalysts (see section 
4.4). Although this kind of functionalized fibrils are relatively easy to assemble, 
only one example of a two-enzyme cascade was discussed in the literature 
(Nussbaumer et al., 2017). Since enzymatic cascade reactions could be used for 
the cell-free synthesis of commodity chemicals, the potential that amyloid fibrils 
hold in this respect have not been investigated to its fulness. Paper IV is an 
important step towards this aim. Here, a three enzymatic cascade (XynA, βXyl, 
ASD) that converts xylan from beechwood to xylonolactone was studied, which 
includes a detailed kinetic analysis of the factors that influence product 
accumulation. 
Our initial idea was to create a modular cascade of functionalized PNFs that 
are separately captured on 0.45 µm filters (Figure 13), similar to a previously 
suggested concept for spider dragline silk (Jansson et al., 2015). In this design, 
the substrate solution is cycled over the filters until the desired product 
Figure 12. A-D Examples of data from the literature converted to Δ[S]QE&'&CD over [S]QE&'&CD and 
fitted to equation (2.).  
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concentration is reached. The advantage is that possible mass transport 
limitations are counteracted by increasing the flow of the substrate solution. 
Suspecting that the filters could be clogged by an improper preparation of the 
beechwood xylan, we were very careful and filtered the substrate solution 
several times through 0.2 µm. Also, an initial test of cycling the substrate over 
empty 0.45 µm filters maintained a stable pressure for 24h. However, once the 
fibrils were placed on the filter, the back pressure increased steadily to sustain a 
reasonable flow rate of 0.5 mL/min, until the filter was completely clogged. A 
plausible explanation is that the initial rather loose packing of the fibrils is 
crushed by the back pressure, which means that flow channels cease to exist. To 
omit these complications, we decided to study a fibril suspension instead. 
The primary investigation focused on the synergy between XynA and βXyl, 
which liberates xylose monomers from beechwood xylan. This catalytic reaction 
was strategically studied by first determining the relative molar ratios of the 
soluble enzymes that yield the highest xylose concentration after a 24 h 
incubation at 37 °C. At 0.4 µM XynA, the xylooligos (xylobiose, xylotriose, 
xylotetraose, xylopentaose) reach their highest concentration during the first 240 
minutes (pH 6). From this point on, their concentration is steadily decreased, and 
xylose concentration is increased, due to the action of βXyl. A 30-molar excess 
Figure 13. The initial concept for implementing the enzymatic cascade includes the enzymes 
XynA, βXyl and ASD immobilized on PNF. These enzymes convert long chained carbohydrates 
(xylan) to xylonolactone. The design relies on capturing the fibrils on 0.45 µm filters, which allows 
substrate cycling over the filter until the desired product concentration is reached. By adjusting the 
flow rate, mass transport limitations could also be decreased. 
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βXyl over XynA yielded 64% xylose with respect to the total product 
concentration.  
This reaction was replicated, but this time the enzymes were displayed on 
Sup35 fibrils (doping frequency 1:0.74 and 1:0.33 for XynA and βXyl fibrils, 
respectively). In fact, this comparison revealed no difference between the 
product yield and the relative xylooligo content, which yet again points towards 
the robustness of our fibrillation approach. The xylose and xylooligo yield 
applying these catalytic fibrils was also quantified using a temperature gradient 
between 33-49 °C, in 5 °C increments at pH 6. The xylose amount released using 
45 °C for 24 h is elevated by 9% compared to 37 °C. However, if the fibrils are 
reused, 45 °C is less appropriate as the fibrils suffer a 50% efficiency decrease 
already after one additional repeat. The most reproducible xylose yield, while 
reusing the fibrils eight times, were obtained at 33 °C. At last, the fibrils were 
also subjected to agitation at 500 and 1,000 rpm.  Surprisingly, the xylose yield 
was increased by 26 % after a 24 h incubation at 37 °C compared to the soluble 
enzymes. We concluded, that the mass transport of the heterogeneous substrate 
is the dominating cause for this effect. 
A unified xylose release and oxidation, by a XynA/βXyl/ASD functionalized 
fibril cocktail was difficult to implement since the reactions have different pH 
and long-term temperature optima. At pH 6.0, 300-fold more ASD would be 
necessary to compensate the loss of activity compared to pH 9.0. However, a 
compromise at pH 7.5 and room temperature, which ensures the long-term 
integrity of fibrils equipped with ASD, reduces the rate of xylose accumulation 
by XynA/βXyl 11-fold. This implies that the hydrolysis of xylan would require 
11 days instead of one. Nevertheless, we have tested this combination at pH 7.5 
and room temperature in an open Eppendorf tube to allow continuous 
oxygenation of the sample, using the molar concentrations 0.4/12/120 µM of 
XynA/βXyl/ASD fibrils. In this reaction xylobiose and xylotriose are almost 
exclusively oxidized over the course of one week, whereas only minor amounts 
of xylose and xylonolactone were detected. Our preliminary hypothesis is that 
βXyl is inhibited by the fast production of xylobionolactone and 
xylotrionolactone. Therefore, additional modifications to the reaction conditions 
are necessary to shift the equilibrium towards xylonolactone.  
A modular cascade setup is a more reasonable strategy that can be executed 
faster and requires less enzyme. The basis of this arrangement is that xylose is 
produced first with a XynA/βXyl cocktail at pH 6 and 37 °C. Subsequently the 
XynA/βXyl fibrils are removed, the pH of the substrate is adjusted to 9.0, and 
replaced with ASD functionalized fibrils that oxidize xylose to xylonolactone. 
We have also tested this strategy and found that 97% of the xylose are oxidized 
after 24 h at room temperature, also using an Eppendorf tube with access to air.  
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4.6 Producing Ready-To-Use Nanofibrils  
Biotechnological applications require scales that are far greater than those 
produced in a research laboratory, which is a real issue, since plenty of brilliant 
inventions fail due to practical problems like upscaling and cost.  
This is why we raised the question of choosing a suitable methodology for 
upscaling the production of amyloid fibrils (Paper III). Short PNF forming 
peptides that are chemically produced are expensive and can therefore not be 
produced on the scales required for industrial applications. Due to the chemicals 
involved for the production of synthetic peptides, the concept would also 
obliterate the whole idea of producing environmentally friendly materials (Diaz-
Caballero et al., 2018). Another route would be to produce the proteins 
heterologously in E. coli. However, this is only an option on a laboratory scale. 
Since E. coli has a poor protein secretion machinery the cells have to be lysed, 
to be able to access the expressed proteins. Subsequently, purification of the 
amyloidogenic peptides is necessary and often requires the use of denaturants, 
which is both expensive and time consuming. Instead of using E. coli to produce 
foreign amyloids an elegant direction is to exploit the inherent capability if E. 
coli to form curli nanofibrils, which are essential for biofilm formation 
(Courchesne et al., 2017, Nguyen et al., 2014, Nussbaumer et al., 2017). The 
currently cheapest source for amyloidogenic proteins is mammalian, for 
example b-lactoglobulin from whey. Even though these proteins could be used 
to create hybrid materials with other nanostructures, the issue is that it is 
extremely inefficient and time consuming to engineer the proteins by genetic re-
design. To produce other amyloids besides curli fibrils from E. coli, the last 
option is to move to other microorganisms that are known for their capability to 
produce high yields of proteins and which have a good protein secretion 
machinery. As a starting point to develop a generic recombinant host for the 
expression of PNF, we chose Komagataella pastoris (K. pastoris), which fulfils 
the above-named requirements.  
In this study we inserted one copy of the gene for Sup35(1-61)-ZZ and two 
copies of the gene for Sup35(1-61) via homologous recombination into the 
genome of K. pastoris and obtained a new strain which we named AG2. The 
genes for the chimeric and carrier proteins were N-terminally linked to the a-
factor, which targeted the proteins for secretion into the extracellular medium. 
The concept was based upon the idea that the exported proteins will aggregate 
into functional fibrils during the cultivation and thereby be separated from other 
contaminating proteins present in the medium, which will stay in solution. After 
successful transformation of K. pastoris we initially screened transformants for 
the production of soluble Sup35(1-61)-ZZ and Sup35(1-61), and based upon 
results using SDS-PAGE, concluded that the proteins were not present in soluble 
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fraction. Instead, we identified a pale green-yellow deposit, which appeared as 
an additional layer on top of the cell pellet after centrifugation of a K. pastoris 
AG2 culture. Analysis of this deposit revealed bright fluorescence with ThT, 
elongated fibrils using TEM, and two protein bands on an SDS-PAGE, which 
correlate with expected sizes for Sup35(1-61) and Sup35(1-61)-ZZ. To separate 
the fibrils from the K. pastoris cells we selectively resuspended the fibrils in 
saline H2O. This is possible since the cell pellet is much heavier and denser than 
the fibril deposit. This approach requires minimal downstream purification and 
the fibrils are ready-to-use after washing with saline H2O only. To proof the 
concept, we produced 35 mg per liter of cell culture of the antibody binding 
nanofibril. 
By choosing to insert a 2:1 ratio of carrier over chimeric protein, we aimed a 
doping frequency of 1:0.5, which is higher than the optimal ratio 1:0.33 (Paper 
I). Interestingly, the material produced in the fermentor had an IgG binding 
capacity of 3.1 mg/mg fibril, which is 67 % more binding capacity compared the 
material that we have assembled using proteins expressed in E. coli (Paper I). In 
addition, the doping frequency was 1:0.12, only 1/3 of the optimized fibrils from 
Paper I. To account for the difference, it has to be considered that the carrier 
proteins were subject to C-terminal proteolytic degradation. As a result, they are 
40% smaller compared to the Sup35(1-61) construct produced in E. coli. 
Additional differences are possibly explained by considering the uncertainty 
with respect to the concentration of Sup35(1-61) and Sup35(1-61)-ZZ. These 
results show that a way to obtain higher IgG binding capacities, would be to trim 
the peptide sequence of the carrier protein even further. Certainly, there has to 
be a balance between how short the carrier proteins can be and the propensity of 
the peptide to efficiently fibrillate in the extracellular medium. The effect of the 
size of the amyloidogenic peptide and the yield needs to be balanced and 
shortening the carrier protein should only have a minor effect on the stability of 
the PNF in terms of mechanical attributes and chemical resistance.  
4.7 Biotechnological Context and Practical Implications 
The idea that amyloid could be used as designable material was launched 18 
years ago, but biotechnological implementation is still on hold. Therefore, I 
would like to discuss the reasons for the slow progression of the PNF technology.  
With respect to amyloid, the main research is conducted on 
neurodegenerative diseases, which is a paramount concern for world-health. 
Since the same acute inducement for the discovery of practical implications of 
amyloid is missing, the field lags behind. Another factor that could contribute to 
the slow progression is that the word ‘amyloid’ is still almost exclusively 
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associated with disease in the public opinion. Others, who are not familiar with 
the field, may not be aware of the common existence of ‘functional amyloid’ and 
the advantageous properties of the material. 
From a material perspective, the protein-based spider silk had a head start 
and was for a long time the main target of research for biotechnological 
utilization. Even though no negative association with respect to silk exists, 
research conducted for more than 40 years (Jannson, 2015) has resulted in only 
few prototype applications by 2018 (Salehi and Scheibel, 2018).     
Compared to spider silk, amyloidogenic peptides are in many respects easier 
to handle and to design. The peptides grant more flexibility regarding the peptide 
length (2 to >100 amino acids). Furthermore, they can be specifically engineered 
with respect to amino acid compositions and charge distribution. If this is 
executed correctly, rational design of amyloidogenic peptides does not alter the 
fibrillation efficiency or the mechanical properties of the assembled fibrils.  
Finally, the peptides self-assemble into fibrils at much lower concentrations.  
A biotechnological challenge that both spider-silk and amyloid materials face 
is that they suffer from the same reduction of mechanical stiffness when the 
nanofibrils are assembled into macrostructures (Kamada et al., 2017). For 
instance, longer amyloid fibrils are more fragile than shorter analogues 
(Knowles and Buehler, 2011).  
On a positive note, in the past three years several extremely comprehensive 
reviews (see section 2.3.5) that summarize demonstrated applications of PNFs 
were published, which shows the accelerating interest and recognition of this 
material scaffold.  
In the subsequent sections, I will review the functionalized nanofibrils 
developed in this work with respect to their biotechnological significance. At the 
end of section 4.7.4, I will once more highlight cost-related questions and their 
practical implications.  
4.7.1 The Antibody Binding Nanofibril  
Monoclonal antibodies (mAB) are a relatively new class of drugs, so called 
protein therapeutics, that are highly successful applied against inflammatory and 
cancer diseases (Shepard et al., 2017). The antibodies are highly specific, 
compared to the classical small organic compounds, and aim to activate the 
innate immune system. Today, more than 57 antibodies are FDA-approved, 
which amounts to a total market value of more than $ 100 billion per year (Grilo 
and Mantalaris, 2018). 
Protein A Sepharose is an affinity medium distributed by GE Healthcare, and 
the main chromatographic method used for purification of mAB. However, the 
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medium is criticized for having a rather low IgG binding capacity and being 
expensive (Shukla et al., 2007, Kelley, 2009, Gagnon, 2012). Compared to the 
protein A Sepharose (drained medium) and the competing PolyBind-Z™ 
(PolyBatics Ltd.), the binding capacity of the ZZ-domain doped optimized 
Sup35(1-61) fibril is at least 20-fold higher (Paper I).  
Therefore, we investigated the suitability of the fibrils for purification of 
human IgG from serum. In this experiment we incubated a ZZ-functionalized 
fibril suspension (both Sup35(1-61) and Ure2(1-80)) with the complex serum 
matrix. The fibrils were sedimented by centrifugation, washed thoroughly with 
tris-buffer (pH 8), before the IgG was eluted with a glycine-HCl buffer (pH 3). 
The protein contents of the different purification steps were analysed with SDS-
PAGE (Figure 14). The purity of the eluted antibodies is almost identical to 
reference samples of protein A Sepharose purified human IgG. The only caveat 
of this protocol is leakage of small fibril fragments during elution, but which can 
be removed with size exclusion chromatography. Since this leakage seems to be 
more severe for Sup35(1-61) than for Ure2(1-80) fibrils, further improvement 
could be achieved by additional optimization, to create a fibril backbone that 
does not leak during elution.  
Figure 14. SDS-PAGE of the purification of human IgG from serum. The numbered arrows I-VII 
refer to: (I) IgG light chain, (II) IgG heavy chain, (III) Sup35(1-61)-ZZ, (IV) Sup35(1-61), (V) 
Ure2(1-80), (VI) Ure2(1-80)-ZZ, and (VII) Albumin. Known amounts of human IgG (Thermo 
Fisher) were included as a reference. 
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Shortly after Paper I was published, GE Healthcare introduced their next 
generation monoclonal antibody (mAB) purification material, MabSelect 
PrismA (GE Healthcare, 2018),with an binding capacity of 80 mg/mL medium. 
Considering that one mL of Sepharose corresponds to 250 µg of dry weight 
medium (Amersham Bioscience, 2003), the approximate corresponding binding 
capacity of MabSelect PrismA is 0.32 mg/mg (Figure 15). With 1.8 mg/mg, the 
IgG binding capacity of our material is still superior by a factor of 5.6. However, 
the ZZ-doped fibrils cannot compete with the optimized IgG binding domain 
from GE Healthcare, which has an exceptional stability. In addition, Sepharose 
is a well-established chromatographic medium that tolerates high flow rates and 
pressure. An advantage of our approach compared to the agarose beads is that 
the antibody binding nanofibrils do not require environmentally hazardous 
chemicals for cross-linking the functional domain to the matrix, as this is the 
case for the Sepharose affinity medium. Nevertheless, in face of this new 
development, it will be extremely challenging to compete with the world-wide 
established antibody affinity medium. Biotechnologically, our fibrils have yet 
another potential application. The high antibody binding capacity of our fibrils 
would be an excellent match to the increase the sensitivity of immunoassays 
(Figure 16) (Men et al., 2009, Men et al., 2016, Leng et al., 2010, Men et al., 
2010). 
Figure 15. Experimentally determined binding capacity of protein A 
Sepharose (dry weight) and Sup35-ZZ fibrils (doping frequency 
1:0.33).   
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4.7.2 Hydrolysis of Antibiotic Contaminations 
The release of non-metabolized antibiotics into the wastewater and ultimately 
into lakes and oceans is a major environmental hazard (Baran et al., 2018). 
Furthermore, this practice favours the development of multi-resistant bacteria, 
which is a world-wide concern for public health (Zhang et al., 2016). Current 
methods to degrade pharmaceutical contaminations include sludge bioreactors, 
UV/H2O2 wastewater treatment, and coagulation (Baran et al., 2018, Guo et al., 
2018, Zhang et al., 2016). The efficiencies of pharmaceutical removal are often 
suboptimal (20-70%) and they produce several non-characterized by-products. 
Certainly, the wastewater reprocessing is an extremely price sensitive market, 
which requires new affordable, well-characterized, and environmentally friendly 
solutions.  
Figure 16. (A) Indirect Immunoassay: An antigen is adsorbed onto an immunoplate and recruits the 
primary antibody. The primary antibody is recognized by the secondary antibody, which is 
conjugated with a fluorophore, thus generating a signal. (B) Using the ZZ-doped PNFs can enhance 
the signal, and thus the sensitivity by linking many more signal generating secondary antibodies to 
one antigen.  
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 The TEM1 functionalized fibrils degrade b-lactam antibiotics such as 
penicillin and ampicillin (Paper II). These and other enzymes that can 
specifically degrade pharmaceuticals could be used in synergy for an 
environmentally friendly method for wastewater treatment. The advantage using 
an enzyme cocktail compared to chemical methods is that the biocatalysts yield 
known products and by-products. However, a practical application of the 
enzyme functionalized fibrils for wastewater treatment would require enormous 
quantities of the material. To implement these and similar applications a major 
research aim should be to develop the methodology for producing functionalized 
amyloid fibrils for a reasonable price (Paper III).   
The enzymatic nanofibrils could be utilized to construct pharmaceutical 
degrading membranes, but the risk for immediate clogging is extremely high, if 
the water is not thoroughly pre-filtered. An alternative would be to fill a pool 
with a fibril suspension, that is allowed to sediment, when the reaction is done. 
In any case, since it is to date not possible to produce the quantities required, this 
method should be reconsidered in the future.  
4.7.3 Enzyme Immobilization and Processing of Xylan Biomass 
A reoccurring argument for reusing enzymes is that the cost of the catalysed 
bioprocess could be significantly reduced (Es et al., 2015). To render enzymes 
reusable, they have to be coupled onto a solid support to attain an irreversible 
separation of the biocatalyst and the substrate solution. Other typical mentioned 
motivations that intend to promote enzyme immobilization in industrial settings 
is the simplicity of post-catalytic enzyme removal and a higher enzyme tolerance 
against harsh conditions. Therefore, the technique of immobilizing enzymes on 
solid materials is a widely researched subject within biotechnology that has 
produced hundreds of applications in recent years (Zhou and Hartmann, 2013). 
This research has also generated a large array of different immobilization 
strategies and promoted the development of materials that are appropriate for 
enzyme coupling (Datta et al., 2013). In particular, nanoscale supports have an 
advantage over classical porous materials as they ensure a high functional 
density (Min and Yoo, 2014). Even though this positively enforced arguments 
are repeatedly used, only very few applications of immobilized enzymes have 
been commercialized (DiCosimo et al., 2013). The authors argue that the main 
justification to utilize immobilized enzymes – a cost reduction – is in the 
majority of cases not relevant, because industrial enzymes are not expensive and 
cost only between 50-500 $/kg (see also section 4.7.4). Instead, the process of 
enzyme immobilization is the cause for a substantial cost, which includes the 
cost of the immobilization matrix, the cross-linking chemicals, the time needed 
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for the immobilization process, and costs related to alterations of enzyme kinetic 
properties.  
Our recent success to produce ready-to-use functionalized nanofibrils with 
K. pastoris while cultivating our yeast-strain in a fermentor (Paper III), could be 
an important discovery that has the potential to simultaneously accomplish 
enzyme production and immobilization. Hence, the additional time and cost for 
immobilizing enzymes would be omitted, which could make the reusable 
biocatalysts relevant for an increasing number of biotechnological applications. 
Furthermore, the demand to develop environmentally-friendly functional 
materials would also be fulfilled. In light of this progress, we wanted to study 
the potential of amyloid fibrils as a tool to assemble complete catalytic cascade 
of immobilized enzymes that synthetize important chemicals. 
 Alternatives to chemical methods usually rely on the utilization of 
engineered microorganisms, but the development of these cellular factories 
demand hundreds of accumulated working years (Hodgman and Jewett, 2012, 
Korman et al., 2017). On the contrary, the development of cell-free biocatalytic 
cascades is expected to be much faster. Other advantages of cell-free catalytic 
systems become evident in Paper IV. In this study it was simple to identify 
problematic steps in the catalytic cascade, adjust the relative enzyme 
concentrations to maximize the product yield, optimize the reaction conditions, 
and develop rational strategies that accelerate the process of biocatalysis. 
The catalytic cascade in Paper IV involved the enzymes XynA, βXyl and 
ASD, which we specifically chose, to explore the option of designing biomass 
processing PNF. Mainly, the reason to utilize biomass is to reduce our societies 
dependency upon petrol-based chemicals (McKenna et al., 2015). Thus, the 
consumption of xylan for this purpose, the second most abundant carbohydrate 
polymer after cellulose, celebrates a growing interest (Michelin et al., 2012). It 
is therefore no surprise that the synergetic catalytic action of xylanase and b-
xylosidase is the target of several recent studies (Biely et al., 2016, Yang et al., 
2014, Malgas et al., 2017). The catalytic hydrolysis of xylan is also important to 
enable fast enzymatic degradation of cellulose, since hemicellulose inhibits 
cellulases (Qing and Wyman, 2011). In conclusion, a combined cocktail of PNFs 
functionalized with cellulases, xylanases, glycosidases and xylosidases could 
become handy to process biomass for the production of second-generation 
biofuels. Since biofuel production is a very price sensitive market (Losordo et 
al., 2016) the process could profit from cheap ready-to-use immobilized and 
reusable enzymes.  
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4.7.4 Cost Perspective 
The following discussion on the cost for producing the PNFs will be limited to 
the antibody binding fibrils (Paper I & III). The motivation is that there are clear 
cost-aims set by the competitor GE Healthcare. Furthermore, the results 
described in Paper III were obtained with the antibody binding PNFs, which 
allow us to make a rough cost estimation. Finally, the discussion of this 
particular material is highly relevant to us, since we recently submitted a patent 
application to protect our invention (Härd et al., 2016). 
The cheapest proteins available today are soy bean protein and cellulases, 
which can be produced in the range of 1-25 $/kg (Liu et al., 2016). However, 
this price is only valid for rough enzyme broths. Certainly, if protein purification 
is required for the intended application, the cost is increased substantially. 
Industrial and medical proteins are produced in various recombinant hosts using 
E. coli, K. pastoris, Aspergillus niger, Bacillus subtilis, Trichoderma reesi, and 
mammalian cell lines. The production levels for these proteins are in the range 
of 4 mg/l of cell culture (Protein-glutamine g-glutamyltransferase), 4 g/l 
(Insulin), 22 g/l (b-Galactosidase), to 100 g/l (Cellulase) (Spohner et al., 2015, 
Shin et al., 1997, Seiboth et al., 2011). A 25,000-fold difference between the 
production yields of this narrow selection of industrial proteins, shows that the 
inquiry of a minimum production yield for PNF to offer a competitive product 
in terms of cost, is very much dependent upon the application.  
The antibody binding material is intended to be applied as a matrix for mAB 
purification and to improve the sensitivity of immunodetection assays. GE 
Healthcare will sell their new affinity medium MabSelect PrismA, for the 
purification of mAB, for not less than $ 28 per ml4. When Sepharose is dried, 
the weight of the material is reduced by a factor of 4. Accordingly, the selling 
price can be estimated to 112 $/g. However, this allows no conclusion with 
respect to the cost of production for the affinity medium since this is a highly 
sensitive information and not publicly available.  
Considering that the production yield of the antibody binding nanofibrils is 
35 mg/l and one batch in a 5L fermentor costs approximately $ 714 (Table 4 
and 5), to produce one gram would currently cost $ 4,080, which is obviously 
not reasonable for an antibody purification material. However, to improve an 
immunodetection assay kit (for example TNFa, 96 well plate for $ 460)5, will 
not consume more than 5 µg fibrils per well (Men et al., 2009). Thus, the  
                                                        
4. Based on an estimate from the precursor material MabSelect SuRe (GE Healthcare) sold by 
Merck. (https://www.sigmaaldrich.com/catalog/product/sigma/ge17543801?lang=en&region=SE, 
last accessed August 9th, 2018) 
5. Assay from Thermo Fisher Scientific (https://www.thermofisher.com/elisa/product/TNF-
alpha-Human-ELISA-Kit/KHC3011, last accessed August 9th, 2018) 
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additional cost for the fibrils of a 96 well plate kit is $ 1.95, and probably 
competitive with respect to estimated 100-fold improvement of the sensitivity.   
To make the PNF technology also commercially feasible for applications that 
require several g or kg of the material, the production has to be scaled to 
industrial size fermenters. Unquestionably, the price per liter of culture in an 
industrial scale fermentor is reduced substantially, but I cannot refer to a 
published estimate from biotechnological companies, since the cost is 
confidential. However, the cost can be roughly estimated by considering that a 
biofuel plant by DuPont can produce second generation bioethanol currently at 
$ 2.9 per liter ethanol (Losordo et al., 2016). The basis of second-generation 
bioethanol production is the release of glucose from cellulose by enzymatic 
hydrolysis. A reasonable assumption is that a 3% (w/w, 30 g) enzyme dosage is 
used to hydrolyze cellulose (Novozymes, 2010). Furthermore, in the best-case 
scenario 0.5-liter ethanol can be obtained from one kg cellulose (Aditiya et al., 
2016). Thus, 60 g enzyme are consumed to obtain one liter of ethanol.  With the 
knowledge that enzymes account for at least 40 % of the cost of bioethanol 
production (Tiwari et al., 2018), we can conclude that 60 g cellulase cost $ 1.2. 
 
 
Table 4. Estimation of the cost to run a 5L fermentor on a laboratory scale. 
 cost ($)/ batch Time (h) 
Fermentor (5L) 600 48 
Laboratory Staff 100 4 
Cultivation Medium 14 / 
Sum 714  
The prices are rough estimates based upon the equipment and the facilities in the laboratory 
from Mats Sandgren.  
 
Table 5. Cost of YPD-Medium components per liter of liquid culture medium. 
Component $ / kg dry weight g / l $ / l 
Peptone 92 20 1.84 
Yeast extract 48 10 0.68 
Glucose 14 20 0.28 
Sum   2.8 
The calculation is based upon medium components from Formedium. A cost of 2.8 $/l of 
medium corresponds to $ 14 for a 5L fermenter. 
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Assuming that Trichoderma reesi expresses 100 g cellulase per liter of cell 
culture means that cultivation of one liter in an industrial size fermentor should 
not cost more than $ 0.7. 
A reasonable aim is to obtain production of the functionalized materials in a 
cost competitive range above 1 g/l. These expression levels in combination with 
the estimated cost of a cultivation in an industrial size fermentor, would all of a 
sudden make applications for antibody purification or similar feasible.  
To engineer K. pastoris AG2 further, time needs to be spent on integrating 
enough copies into the high expression positions of the genome, and to optimize 
the cultivation conditions. Additional strategies to engineer the PNF producer is 
to remove antibiotic resistant makers, proteases, and genes for non-essential 
proteins in order to save energy for the target protein. This task can be done with 
the newly developed and well documented CRIPSR/Cas9 genome editing 
technology. 
If these attempts fail, it will be inevitable to screen additional production 
hosts. The minimal requirements are that the cultivation is scalable, and that 
simple media components are needed for efficient growth of the 
microorganisms. These requirements exclude cell-free systems as well as 
mammalian and insect cell expression systems. As an alternative to E. coli, 
Bacillus subtilis could be a feasible option since the bacteria grow rapidly and 
can produce extracellular protein above the g/L range (Zhang et al., 2017, 
Westers et al., 2004). Other more exotic options are Lactococcus lactis 
(Jorgensen et al., 2014), or Ralstonia eutropha that can also express up to 10 g/L 
of heterologous extracellular protein (Barnard et al., 2004). A greater effort 
would be to engineer filamentous fungi. Aspergillus niger and Trichoderma 
reesi are the workhorses for industrial cellulase and can produce amounts 
exceeding 100 g/L. However, it is to date not possible to reach these expression 
levels for non-cellulase heterologous proteins (Nevalainen and Peterson, 2014, 
Su et al., 2012). A better choice would be to employ Myceliophthora 
thermophila since this fungi can effectively produce heterologous protein in the 
g/L range (Hans et al., 2011).  
To find a suitable expression host and engineer the microorganism in a way 
to get more than 1 g/L is a time and money-consuming task, that is mostly of 
industrial relevance and must be executed together with industrial partners.  
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I hope that I could convince the reader of this work, that the development of PNF 
technology is a worthy research investment that could provide novel solutions 
to current biotechnological aims of modern society. Among others, the major 
aims of biotechnological applications can be grouped into five categories: 1) the 
development of sustainable synthesis pathways, using biocatalysts or 
microorganisms, for the production of fine chemicals in order to reduce the 
environmental impact of industry; 2) to assemble biocompatible and degradable 
materials that can reduce society’s dependency on synthetic plastics; 3) to 
produce designable self-assembling materials by applying the bottom-up 
approach of nanotechnology; 4) to improve healthcare and diagnostics; and 5) 
to minimize the anthropogenic environmental impact in general. So far, PNF 
materials developed on laboratory scale promote all of the above-mentioned 
aims. Functionalized fibrils can capture CO2 (® 5), are used to enrich rare earth 
metals (® 3, 5), are applied to assemble conducting nanowires (® 3), and are 
novel alternatives to synthetic plastics (® 2) (Ye et al., 2018). Furthermore, in 
this work I have developed fibrils that can be employed as an antibody 
purification matrix (® 4), serve as a filter for antibiotic degradation (® 5), and 
process xylan biomass using an immobilized enzymatic cascade (® 1). 
Nevertheless, the PNF technology is in some aspects still in its infancy, and 
requires additional developmental work to make the technology commercially 
competitive. 
An imminent study should evaluate how the degree of functionality 
influences the mechanical properties of amyloid fibrils. In the next stage a 
thorough investigation may focus on the difficulty to transfer the advantageous 
material properties of PNF to structures with macro-morphologies. In the best-
case scenario, macro-structures should possess the same mechanical stiffness as 
the individual nanofibril. Furthermore, a targeted study to elucidate and confirm 
5 Concluding Remarks and Future 
Perspectives  
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the safety of functional amyloid, especially for in vivo applications, is inevitable. 
Finally, the production levels of functionalized ready-to-use PNF for different 
applications in order to be profitable should be meticulously evaluated. The final 
task of upscaling the production of the PNF is a major effort that needs to be 
tackled together with industrial partners. 
In summary, amyloid fibrils are a versatile material. The difficulty is not to 
design new materials, but to make the transition from lab-scale proof of concept 
deigns to commercially competitive solutions for current biotechnological 
problems. To accelerate this transition, close collaboration with industry is 
necessary, to develop the technology for specific relevant purposes. 
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Proteins are large biomolecules, which are the basic building blocks of life. In 
fact, proteins steer cellular and intracellular functions, accelerate biochemical 
reactions, and act as signal transducers. Another important function of proteins 
is that these biomolecules can be assembled into different materials. These 
materials possess a large range of properties, which vary from rigid to elastic. 
Due to the versatility of protein materials they are used for many different 
purposes. Among others, proteins are building blocks of hair, nail, bone and skin.  
A protein is a long chain of covalently bound aminoacids, which fold into 
well-defined 3D structures. The 3D-structure determines the function of a 
protein. However, these constructs are rather fragile, which means that proteins 
are prone to refold and aggregate. To prevent this from happening, advanced 
cellular security mechanisms take care of misfolded proteins. However, 
mutations, stress and failure of the security mechanisms result in accumulation 
of aggregated proteins in vital organs. This is the cause for severe diseases that 
are more likely to occur at an advanced age and limits the quality of life. Most 
common diseases are Alzheimer’s, Parkinson’s, and diabetes type II.  
In the beginning of this millennium, new data suggested that these aggregates 
consist of highly ordered, nanosized fibrils. Then, researchers also discovered 
that protein nanofibrils are not only the origin of diseases, but that the high 
stability of these aggregates are utilized by simple microorganisms, and also by 
higher multicellular organisms including humans. This insight was the key to 
recognize the enormous potential of the fibrils for biotechnological applications. 
From material point of view, the mechanical strength of the fibrils is 
comparable to spider silk, ‘natures high performance polymer’. Due to the small 
size of the protein fibrils – the diameter is 10,000 times thinner than a human 
hair – they have a really large surface area, which makes them attractive for all 
kind of applications. Since proteins are designable by changing the DNA 
sequence, likewise the fibril properties can be adjusted through the genetic code. 
This makes it possible to decorate the fibrils with other proteins that perform a 
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specific function, without using chemistry. Therefore, the protein nanofibrils, 
are also a very promising material from an environmental perspective. In 
principle, only microorganisms are necessary to produce the fibrils.  
In this work I have assembled fibrils that can be used as a material to purify 
antibodies, if developed further. The significance of this finding is that 
monoclonal antibodies are a new class of medication that aim to activate the 
innate immune systems, in order to reduce common side effects that are typical 
for small compound drugs. The demand for these therapeutically antibodies 
increases at an astonishing rate, which requires new, faster and cheaper ways to 
purify them. A possible solution to this new demand are my antibody binding 
fibrils that have a 5-time increased binding capacity, compared to any existing 
commercially available product.  
Antibiotic contaminations are another severe concern that threatens the 
effectiveness of future healthcare. Minor antibiotic contaminations in the 
environment can result in the development of resistances of pathological 
microorganisms against these anti-microbial agents. Chemical methods that 
degrade antibiotics are not 100 % efficient, and could produce unwanted by-
products. Therefore, I developed a biochemical method that employs enzymes 
which are linked to the protein nanofibrils instead. In this study I was also able 
to show that the enzyme linked to the fibril has the same catalytic efficiency as 
the normal enzyme in solution.   
To utilize renewable resources and consequentially reduce the dependency 
of our society on petrol-based products is another research area that is very 
famous. Yet again, I have developed fibrils that are linked to a cascade of 
enzymes, which makes the enzymes reusable. I have also successfully tested to 
process biomass from beechwood using the enzymatic fibril cascade. This 
method could be an important step towards making biomass utilization cheaper.  
The large-scale production of the fibrils is a big concern, and one of the 
reasons why none of the fibrils reported in scientific literature have reached 
commercial maturity yet. The transition from the laboratory to the real-world 
application is not a simple task, which requires a lot of work that goes beyond 
basic research. As a first step towards this end goal, have genetically engineered 
a yeast that produces functional nanofibrils in the cultivation medium. After 
cultivation the fibrils are ready-to-use and need only to be rinsed with water to 
completely remove the yeast cells. This method still requires some optimization, 
but is definitely appropriate for upscaling.  
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